Company profile for Curevo Vaccine

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic ...
Curevo will combine excellence in protein science and adjuvant technology to speed safe and highly effective vaccines from the bench through clinical development. Curevo will focus on vaccine-preventable illnesses that are common in both the Asian and US markets and for which current vaccine products are not available. Curevo’s goal is to rapidly advance innovative new vaccine candidates from research laboratory to clinic by joining forces with South Korean Mogam Institute for Biomedical Research, GC Pharma, and the Infectious Disease Research Institute based in Seattle, Washington.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
188 E Blaine St, 127, Seattle, Washington 98102, US
Telephone
Telephone
+1 (206) 492-5722
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/gc-biopharma-secures-cmo-rights-for-shingles-vaccine-from-curevo-vaccine-302581671.html

PR NEWSWIRE
13 Oct 2025

https://www.globenewswire.com/news-release/2025/06/02/3091653/0/en/Curevo-Enrolls-First-Participants-in-Phase-2-Extension-Trial.html

GLOBENEWSWIRE
02 Jun 2025

https://www.globenewswire.com/news-release/2025/03/17/3043632/0/en/Curevo-Raises-110-Million-to-Advance-Amezosvatein-Shingles-Vaccine.html

GLOBENEWSWIRE
17 Mar 2025

https://www.globenewswire.com/news-release/2025/01/12/3008052/0/en/Curevo-Announces-Positive-Updated-Phase-2-Data-for-Amezosvatein-Shingles-Vaccine.html

GLOBENEWSWIRE
12 Jan 2025

https://www.globenewswire.com/news-release/2025/01/08/3006481/0/en/Curevo-Vaccine-to-present-at-the-43rd-Annual-J-P-Morgan-Healthcare-Conference.html

GLOBENEWSWIRE
08 Jan 2025

https://www.globenewswire.com/news-release/2024/10/31/2972262/0/en/Curevo-Presents-Positive-Shingles-Vaccine-Outcomes-Data.html

GLOBENEWSWIRE
31 Oct 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty